Dravet Syndrome Market Size in 7MM is expected to witness a major change in the study period 2019-2032

Dravet Syndrome Market is expected to witness a significant positive shift owing to the positive outcomes of several products during the developmental stage by key players such as GW Pharmaceuticals, Takeda, Stoke Therapeutics, and others.

The Dravet Syndrome market report provides current treatment practices, emerging drugs, Dravet Syndrome market share of the individual therapies, current and forecasted Dravet Syndrome market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Dravet Syndrome treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Dravet Syndrome market.

Key takeaways from the Dravet Syndrome Market Report
• According to the DelveInsight estimates, in Japan total incident cases of Dravet Syndrome have been estimated around 2,800 cases in 2022, which is estimated to increase by 2032.
• According to Dravet Syndrome Foundation (2022), a recent US epidemiology study concluded that Dravet Syndrome is twice as common as previously recognized, affecting 1:15,700 infants, 80% of whom have an SCN1A mutation.
• The leading Dravet Syndrome Market Companies includes GW Pharmaceuticals, Takeda, Stoke Therapeutics, and others.
• Promising Dravet Syndrome Pipeline Therapies includes EPIDIOLEX, TAK-935 (soticlestat), STK-001, and others.

Discover which therapies are expected to grab the major Dravet Syndrome market share, click here for Dravet Syndrome Market Research Report @ https://www.delveinsight.com/sample-request/dravet-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dravet Syndrome Overview
Dravet Syndrome (DS) is a severe form of epilepsy characterized by frequent, prolonged seizures often triggered by high body temperature (hyperthermia), developmental delay, speech impairment, ataxia, hypotonia, sleep disturbances, and other health problems. Dravet Syndrome Foundation, states that DS is a rare, catastrophic, lifelong form of epilepsy that begins in the first year of life with frequent and/or prolonged seizures. Previously known as Severe Myoclonic Epilepsy of Infancy (SMEI), it affects 1:15,700 individuals, 80% of whom have a mutation in their SCN1A gene.

Dravet Syndrome Epidemiology Segmentation in the 7MM

• Total Dravet Syndrome Incident Cases
• Dravet Syndrome Age-incident Cases
• Dravet Syndrome Gender-specific Cases
• Total Dravet Syndrome Diagnosed Cases
• Dravet Syndrome Mutation-specific Incident Cases
• Total Dravet Syndrome Treated Cases

Download the report to understand which factors are driving Dravet Syndrome market trends, click here for Dravet Syndrome Market Forecast @ https://www.delveinsight.com/sample-request/dravet-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dravet Syndrome Market Insights
The total direct and indirect costs associated with such frequent seizures can be significant, as Dravet Syndrome has both an emotional and an economic effect on caregivers and families. Moreover, most patients follow a course of developmental delay with cognitive, motor and behavioral deficits that persist into adulthood. Dravet syndrome severely impacts quality of life for patients, families, and caregivers due to the high physical, emotional, caregiving, and financial burden associated with the disease. Many studies have highlighted the importance of accurate and early diagnosis in Dravet Syndrome which will lead to avoidance of medications that may exacerbate seizures. Additionally, importance of a multi-disciplinary approach and careful planning for management of episodes of status epilepticus leading to improved outcomes have been understood.

Dravet Syndrome Emerging Therapies and Key Companies
• TAK-935 (soticlestat) (Takeda)
• STK-001 (Stoke Therapeutics)
• FINTEPLA (fenfluramine hydrochloride) (UCB)
• EPIDIOLEX (Jazz Pharmaceuticals)

Learn more about the Dravet Syndrome FDA-approved drugs, click here for Dravet Syndrome Emerging Drugs & Companies and Dravet Syndrome Treatment Market @ https://www.delveinsight.com/sample-request/dravet-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Dravet Syndrome Market Research Report

• Coverage- 7MM
• Dravet Syndrome Market Companies- GW Pharmaceuticals, Takeda, Stoke Therapeutics, and others.
• Dravet Syndrome Pipeline Therapies- EPIDIOLEX, TAK-935 (soticlestat), STK-001, and others.
• Dravet Syndrome Market Dynamics: Dravet Syndrome Market Drivers and Barriers

To discover more about Dravet Syndrome Market Drugs in development, click here for Dravet Syndrome Market Dynamics and Dravet Syndrome Market Drivers & Barriers @ https://www.delveinsight.com/sample-request/dravet-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Executive Summary of Dravet Syndrome
3. Competitive Intelligence Analysis for Dravet Syndrome
4. Dravet Syndrome: Market Overview at a Glance
5. Dravet Syndrome: Disease Background and Overview
6. Patient Journey
7. Dravet Syndrome Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Dravet Syndrome Unmet Needs
10. Key Endpoints of Dravet Syndrome Treatment
11. Dravet Syndrome Marketed Products
12. Dravet Syndrome Emerging Therapies
13. Dravet Syndrome: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Dravet Syndrome
17. KOL Views
18. Dravet Syndrome Market Drivers
19. Dravet Syndrome Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

To read more about the Dravet Syndrome market forecast of the report, click here for Dravet Syndrome Market Trends and Insights @ https://www.delveinsight.com/sample-request/dravet-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

This release was published on openPR.